Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Daridorexant on Sleep, Daytime Alertness, and Smoking During Abstinence
NCT07328594Phase 4Not yet recruiting
- Sponsor
- Legacy Health
- Start
- Feb 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of daridorexant in Tobacco Use Disorder (TUD) and Insomnia (2 arms), sponsored by Legacy Health. Primary endpoints: Sleep Quality at 3 weeks, Daytime alertness at 3 weeks and 5 more. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
daridorexant
03
Conditions
Tobacco Use Disorder (TUD)Insomnia
Beyond the preview
Go deeper on NCT07328594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07328594.